Appropriate management of axial spondyloarthritis

Sean P. LaSalle, Atulya (Atul) Deodhar

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

The management of axial spondyloarthritis includes a structured baseline assessment of the disease and follow-up of treatment efficacy using validated instruments. The treatment will depend on the severity and predominant manifestations of the disease. The cornerstone of management remains physical therapy and nonsteroidal anti-inflammatory drugs. Disease-modifying antirheumatic drugs such as sulfasalazine have shown efficacy only in treating peripheral arthritis, whereas thalidomide and Pamidronate have shown some efficacy in treating axial inflammation. Anti-tumor necrosis factor-α agents are an efficacious option for treating signs and symptoms of axial disease, peripheral arthritis, and enthesitis, and for improving functional outcomes. They have not shown efficacy in reducing radiographic progression in axial disease. Recent evidence suggests that the new bone formation in ankylosing spondylitis may be due to upregulation of Wnt signaling in the osteoblastic pathway secondary to low serum DKK-1 levels, which are further suppressed by tumor necrosis factor inhibitor therapy.

Original languageEnglish (US)
Pages (from-to)375-382
Number of pages8
JournalCurrent Rheumatology Reports
Volume9
Issue number5
DOIs
StatePublished - Oct 2007

Fingerprint

pamidronate
Arthritis
Tumor Necrosis Factor-alpha
Sulfasalazine
Antirheumatic Agents
Thalidomide
Ankylosing Spondylitis
Osteogenesis
Signs and Symptoms
Anti-Inflammatory Agents
Up-Regulation
Inflammation
Therapeutics
Serum
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Rheumatology

Cite this

Appropriate management of axial spondyloarthritis. / LaSalle, Sean P.; Deodhar, Atulya (Atul).

In: Current Rheumatology Reports, Vol. 9, No. 5, 10.2007, p. 375-382.

Research output: Contribution to journalArticle

@article{081c9622a544417392861712d0b1179a,
title = "Appropriate management of axial spondyloarthritis",
abstract = "The management of axial spondyloarthritis includes a structured baseline assessment of the disease and follow-up of treatment efficacy using validated instruments. The treatment will depend on the severity and predominant manifestations of the disease. The cornerstone of management remains physical therapy and nonsteroidal anti-inflammatory drugs. Disease-modifying antirheumatic drugs such as sulfasalazine have shown efficacy only in treating peripheral arthritis, whereas thalidomide and Pamidronate have shown some efficacy in treating axial inflammation. Anti-tumor necrosis factor-α agents are an efficacious option for treating signs and symptoms of axial disease, peripheral arthritis, and enthesitis, and for improving functional outcomes. They have not shown efficacy in reducing radiographic progression in axial disease. Recent evidence suggests that the new bone formation in ankylosing spondylitis may be due to upregulation of Wnt signaling in the osteoblastic pathway secondary to low serum DKK-1 levels, which are further suppressed by tumor necrosis factor inhibitor therapy.",
author = "LaSalle, {Sean P.} and Deodhar, {Atulya (Atul)}",
year = "2007",
month = "10",
doi = "10.1007/s11926-007-0060-8",
language = "English (US)",
volume = "9",
pages = "375--382",
journal = "Current Rheumatology Reports",
issn = "1523-3774",
publisher = "Current Science, Inc.",
number = "5",

}

TY - JOUR

T1 - Appropriate management of axial spondyloarthritis

AU - LaSalle, Sean P.

AU - Deodhar, Atulya (Atul)

PY - 2007/10

Y1 - 2007/10

N2 - The management of axial spondyloarthritis includes a structured baseline assessment of the disease and follow-up of treatment efficacy using validated instruments. The treatment will depend on the severity and predominant manifestations of the disease. The cornerstone of management remains physical therapy and nonsteroidal anti-inflammatory drugs. Disease-modifying antirheumatic drugs such as sulfasalazine have shown efficacy only in treating peripheral arthritis, whereas thalidomide and Pamidronate have shown some efficacy in treating axial inflammation. Anti-tumor necrosis factor-α agents are an efficacious option for treating signs and symptoms of axial disease, peripheral arthritis, and enthesitis, and for improving functional outcomes. They have not shown efficacy in reducing radiographic progression in axial disease. Recent evidence suggests that the new bone formation in ankylosing spondylitis may be due to upregulation of Wnt signaling in the osteoblastic pathway secondary to low serum DKK-1 levels, which are further suppressed by tumor necrosis factor inhibitor therapy.

AB - The management of axial spondyloarthritis includes a structured baseline assessment of the disease and follow-up of treatment efficacy using validated instruments. The treatment will depend on the severity and predominant manifestations of the disease. The cornerstone of management remains physical therapy and nonsteroidal anti-inflammatory drugs. Disease-modifying antirheumatic drugs such as sulfasalazine have shown efficacy only in treating peripheral arthritis, whereas thalidomide and Pamidronate have shown some efficacy in treating axial inflammation. Anti-tumor necrosis factor-α agents are an efficacious option for treating signs and symptoms of axial disease, peripheral arthritis, and enthesitis, and for improving functional outcomes. They have not shown efficacy in reducing radiographic progression in axial disease. Recent evidence suggests that the new bone formation in ankylosing spondylitis may be due to upregulation of Wnt signaling in the osteoblastic pathway secondary to low serum DKK-1 levels, which are further suppressed by tumor necrosis factor inhibitor therapy.

UR - http://www.scopus.com/inward/record.url?scp=35348982966&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=35348982966&partnerID=8YFLogxK

U2 - 10.1007/s11926-007-0060-8

DO - 10.1007/s11926-007-0060-8

M3 - Article

VL - 9

SP - 375

EP - 382

JO - Current Rheumatology Reports

JF - Current Rheumatology Reports

SN - 1523-3774

IS - 5

ER -